Diabetes has a massive social and economic impact on America with 30 million people affected at a yearly cost of $314 billion, mostly to treat the associated vascular complications. These complications, including diabetic kidney disease (DKD) develop silently over 10-20 years and no new biomarkers for their early detection had been developed, while existing tests have significant limitations. A major cause of diabetic complications occurs through chemical pathways producing sugar-derived Advanced Glycation End Products (AGEs), which silently accumulate in vascular tissues in those who are most susceptible to kidney failure and blood vessel damage. To prove their predictive value, we have developed LC-triple quadrupole methods to measure specific lysine and arginine derived AGEs, and applied them to landmark clinical outcome studies of type 1 (Natural History of Diabetic Nephropathy Study) and type 2 diabetes (Pima Indian Nephropathy Study), where progression of DKD was quantified by renal biopsy and clinical outcomes. Using the data from these studies, PreventAGE Healthcare is able to utilize a patient’s blood sample to quantitate selected Advanced Glycation End Products (AGEs) in our CLIA certified lab using proprietary algorithms that predict risk of developing DKD during the early stages before significant damage has occurred. Based on this information, health care providers and patients are given a proprietary Complications Propensity Assessment (Compass™ ) report that contains the prognostic information necessary to make proactive and personalized care decisions. Identification of risk at this stage of disease allows early, appropriate and more aggressive treatments for patients at greatest risk when these treatments can delay, reduce, or reverse complications and their associated suffering, mortality, and expense. To make this test the standard of care in diabetes, our centrally located laboratory can provide our services more broadly to meet the needs of the general medical community as well as the patients that they care for.

Advanced glycation end products as predictors of diabetic complications

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.